Department of Medicine, New York Medical College, Valhalla, New York, USA.
Department of Pharmacology, New York Medical College, Valhalla, New York, USA.
Stem Cells Transl Med. 2017 Mar;6(3):992-1005. doi: 10.5966/sctm.2016-0095. Epub 2016 Oct 5.
Accumulation of myofibroblasts is a hallmark of renal fibrosis. A significant proportion of myofibroblasts has been reported to originate via endothelial-mesenchymal transition. We initially hypothesized that exposing myofibroblasts to the extract of endothelial progenitor cells (EPCs) could reverse this transition. Indeed, in vitro treatment of transforming growth factor-β1 (TGF-β1)-activated fibroblasts with EPC extract prevented expression of α-smooth muscle actin (α-SMA); however, it did not enhance expression of endothelial markers. In two distinct models of renal fibrosis-unilateral ureteral obstruction and chronic phase of folic acid-induced nephropathy-subcapsular injection of EPC extract to the kidney prevented and reversed accumulation of α-SMA-positive myofibroblasts and reduced fibrosis. Screening the composition of EPC extract for cytokines revealed that it is enriched in leukemia inhibitory factor (LIF) and vascular endothelial growth factor. Only LIF was capable of reducing fibroblast-to-myofibroblast transition of TGF-β1-activated fibroblasts. In vivo subcapsular administration of LIF reduced the number of myofibroblasts and improved the density of peritubular capillaries; however, it did not reduce the degree of fibrosis. A receptor-independent ligand for the gp130/STAT3 pathway, hyper-interleukin-6 (hyper-IL-6), not only induced a robust downstream increase in pluripotency factors Nanog and c-Myc but also exhibited a powerful antifibrotic effect. In conclusion, EPC extract prevented and reversed fibroblast-to-myofibroblast transition and renal fibrosis. The component of EPC extract, LIF, was capable of preventing development of the contractile phenotype of activated fibroblasts but did not eliminate TGF-β1-induced collagen synthesis in cultured fibroblasts and models of renal fibrosis, whereas a receptor-independent gp130/STAT3 agonist, hyper-IL-6, prevented fibrosis. In summary, these studies, through the evolution from EPC extract to LIF and then to hyper-IL-6, demonstrate the instructive role of microenvironmental cues and may provide in the future a facile strategy to prevent and reverse renal fibrosis. Stem Cells Translational Medicine 2017;6:992-1005.
肌成纤维细胞的积累是肾脏纤维化的一个标志。据报道,相当一部分肌成纤维细胞起源于内皮-间充质转化。我们最初假设,将肌成纤维细胞暴露于内皮祖细胞(EPC)提取物中可以逆转这种转化。事实上,体外将转化生长因子-β1(TGF-β1)激活的成纤维细胞用 EPC 提取物处理可阻止α-平滑肌肌动蛋白(α-SMA)的表达;然而,它并没有增强内皮标记物的表达。在两个不同的肾脏纤维化模型中——单侧输尿管梗阻和叶酸诱导的肾病慢性期——将 EPC 提取物皮下注射到肾脏中可以预防和逆转α-SMA 阳性肌成纤维细胞的积累,并减少纤维化。筛选 EPC 提取物中的细胞因子组成发现,它富含白血病抑制因子(LIF)和血管内皮生长因子。只有 LIF 能够减少 TGF-β1 激活的成纤维细胞向肌成纤维细胞的转化。体内皮下给予 LIF 可减少肌成纤维细胞的数量并改善肾小管周围毛细血管的密度;然而,它并没有减少纤维化的程度。gp130/STAT3 通路的受体非依赖性配体,高白细胞介素-6(hyper-IL-6),不仅诱导多能性因子 Nanog 和 c-Myc 的下游强烈增加,而且表现出强大的抗纤维化作用。总之,EPC 提取物可预防和逆转成纤维细胞向肌成纤维细胞的转化和肾脏纤维化。EPC 提取物的成分 LIF 能够阻止激活的成纤维细胞收缩表型的发展,但不能消除 TGF-β1 在培养的成纤维细胞和肾脏纤维化模型中诱导的胶原合成,而受体非依赖性 gp130/STAT3 激动剂 hyper-IL-6 可预防纤维化。总之,这些研究通过从 EPC 提取物到 LIF 再到 hyper-IL-6 的演变,证明了微环境线索的指导作用,并可能为未来预防和逆转肾脏纤维化提供一种简便的策略。《干细胞转化医学》2017 年;6:992-1005。